Loading…
← CockpitCompetitor Analysis › 300406.SZ Beijing Strong Biotechnologies Inc Class AOpen in the cockpit ↗

Beijing Strong Biotechnologies Inc Class A300406.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese biotechnology company selling in-vitro diagnostic reagents; exact test-menu scope not fully confirmed.

Momentum leader 92
Mkt cap
$1.13B
US dollars, full cap
Free float
49%
of shares outstanding
$/day
$16.7M
20-day average traded
Fwd P/E
18.2×
forward earnings
ROIC−WACC
+3.7 pp
WACC 6.3%
Hurdle
-8 pp
Req g minus delivered
Next earnings
131 days
29 Mar 2027
Close · CNYCN¥12.60
1D-1.5%
1W-1.8%
1M+5.4%
3M+4.7%
6M-3.5%
YTD-3.6%
1Y-7.8%
ATR %2.9%
52w lowhigh21.5% off high

What Beijing Strong Biotechnologies does

Chinese biotechnology company selling in-vitro diagnostic reagents; exact test-menu scope not fully confirmed.

Products and services

  • IVD reagents

Customers

  • Hospital laboratories

Where it sits in the supply chain

  • Health Care
  • In-vitro diagnostics

Moat: none

Headquarters: Beijing, China · Employees: 998

Beijing Strong Biotechnologies at a glance

Size Beijing Strong Biotechnologies (300406.SZ) is a China Health Care company (Medical Specialties) with a market value of $1.13B, the 1927th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.60 on 18 Nov 2026.

Performance Over six months the shares fell 3.5%, against -9.9% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue fell 4.1% over the last twelve months (peer median +10.4%); the operating margin is 35.9% (peer median 8.0%).

Valuation It trades at 18.2× forward earnings against a peer median of 23.9× (5th cheapest of 12).

Price implies For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -8 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 3.7 points above its cost of capital (6.3% WACC).

Next results Next results expected around 29 Mar 2027 (exchange calendar; dates can move).

Relative performance

9010021 May 202621 Aug 202618 Nov 2026300406.SZ 98Peer median 88
Six months, rebased to 100: Beijing Strong Biotechnologies against the median of its 20 peers (local-currency closes).

Beijing Strong Biotechnologies financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.37BCN¥1.34BCN¥1.65BCN¥1.73BCN¥1.50B
Revenue growth—-19%-5%+15%—
Gross profitCN¥1.12BCN¥1.01BCN¥1.23BCN¥1.24BCN¥1.07B
EBITDAn/aCN¥479MCN¥705MCN¥674MCN¥555M
Net incomeCN¥251MCN¥190MCN¥538MCN¥524MCN¥389M
Free cash flowCN¥559MCN¥526MCN¥568MCN¥442MCN¥310M
Capital expenditureCN¥21.5MCN¥39.2MCN¥67.6MCN¥148MCN¥96.5M
Total debtCN¥1.10BCN¥1.07BCN¥1.18BCN¥1.19BCN¥1.12B

Quarterly statements and history in the cockpit →

Beijing Strong Biotechnologies competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%688161DRTSATEC214150IARTTNDM301101688622SIBN2675IRMD688050CSTLEUZ6882896000553010216523NVCR300406.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Beijing Strong Biotechnologies is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×50×100×688161ATEC214150IART3011012675IRMD6882896523300406.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Beijing Strong Biotechnologies is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%+60%0%20%40%60%688161214150IART301101IRMD688050CSTLEUZ3010216523300406.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Beijing Strong Biotechnologies is the large dot.

Beijing Strong Biotechnologies competitors and peer comparison

How Beijing Strong Biotechnologies compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Beijing Strong Biotechnologies against its 20 peers (data as of 18 Nov 2026)
Measure300406.SZPeer medianRank in peer set
1-month return+5.4%-6.0%4th highest of 21
6-month return-3.5%-9.9%8th highest of 20
Distance from 52-week high-21.5%-37.5%3rd highest of 21
Revenue growth (TTM)-4.1%+10.4%4th lowest of 19
Operating margin35.9%8.0%3rd highest of 20
Forward P/E18.2×23.9×5th cheapest of 12
Growth the price implies (Req g, 7 yrs)1.7%9.6%3rd least demanding of 11
Growth delivered (Del g)+9.9%+10.4%6th highest of 11
Hurdle (Req g minus delivered)-8.2 pp-1.5 pp3rd least demanding of 11
ROIC minus cost of capital+3.7 pp-2.5 pp6th highest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Beijing Strong Biotechnologies 300406.SZChina$1.13B-4%-4%36%18.2×1.7%+9.9%
Shandong Weigao Orthopaedic Device 688161.SSChina$1.14B-29%-6%18%24.9×11.3%-3.5%
Alpha Tau Medical DRTSUnited States$1.11B+7%n/an/an/an/an/a
Alphatec ATECUnited States$1.10B-14%+15%-3%15.1×n/an/a
Freenome FRNMUnited States$1.08Bn/an/a36%n/an/an/a
CLASSYS 214150.KSSouth Korea$1.08B-60%+16%43%13.7×-9.2%+34.5%
Integra LifeSciences IARTUnited States$1.08B-10%+1%12%6.0×5.9%+3.6%
Tandem Diabetes Care TNDMUnited States$1.19B+13%+7%-2%n/an/an/a
Mingyue Optical Lens 301101.SZChina$1.07B-4%+14%25%31.6×8.8%+8.8%
Guangzhou Hexin Instrument 688622.SSChina$1.06B+21%-29%-74%n/an/an/a
SI-BONE SIBNUnited States$1.06B+59%+14%-8%n/an/an/a
Shenzhen Edge Medical 2675.HKHong Kong$1.21B-51%+132%2%120.2×n/an/a
IRadimed IRMDUnited States$1.05B-9%+11%32%34.3×18.5%+21.5%
Eyebright Medical Technology (Beijing) 688050.SSChina$1.21B-16%+21%16%23.9×10.3%+40.3%
Castle Biosciences CSTLUnited States$1.03B+67%+10%-7%n/a57.7%+40.6%
Eckert & Ziegler EUZ.DEGermany$1.03B-2%+4%26%18.5×7.7%+12.1%
Sansure Biotech 688289.SSChina$1.24B-17%-1%1%35.6×n/an/a
Beijing Wandong Medical Technology 600055.SSChina$1.03B-26%-11%-33%n/an/an/a
Inno Laser Technology 301021.SZChina$1.03B-33%+17%9%n/a50.8%+8.6%
PHC 6523.TJapan$1.02B+34%+3%8%7.5×-4.0%+3.5%
NovoCure NVCRUnited States$1.25B-40%+13%-17%n/an/an/a

Questions

Which companies are Beijing Strong Biotechnologies's closest peers?
The cockpit's peer set: Shandong Weigao Orthopaedic Device (688161.SS), Alpha Tau Medical (DRTS), Alphatec (ATEC), Freenome (FRNM), CLASSYS (214150.KS), Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Mingyue Optical Lens (301101.SZ).
Is Beijing Strong Biotechnologies expensive compared with its peers?
On forward p/e it trades at 18.2× against a peer median of 23.9×, 5th cheapest of 12 in its peer set. For today's price to make sense, revenue must grow about 2% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -8 pp: the price already allows for a slowdown.
How has Beijing Strong Biotechnologies stock performed?
Over six months to 18 Nov 2026 the shares returned -3.5% against -9.9% for the median peer; over one year -7.8%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.